Scholar Rock Revenue and Competitors
Estimated Revenue & Valuation
- Scholar Rock's estimated annual revenue is currently $18.2M per year.
- Scholar Rock received $47.0M in venture funding in January 2018.
- Scholar Rock's estimated revenue per employee is $95,789
- Scholar Rock's total funding is $358M.
- Scholar Rock's current valuation is $710.2M. (January 2022)
Employee Data
- Scholar Rock has 190 Employees.
- Scholar Rock grew their employee count by 30% last year.
Scholar Rock's People
Name | Title | Email/Phone |
---|---|---|
1 | SVP, Technical Operations | Reveal Email/Phone |
2 | VP, Apitegromab Program Lead (Spinal Muscular Atrophy) | Reveal Email/Phone |
3 | VP, Finance and Controller | Reveal Email/Phone |
4 | VP, Head Biometrics | Reveal Email/Phone |
5 | General Counsel & Corporate Secretary | Reveal Email/Phone |
6 | VP IT | Reveal Email/Phone |
7 | SVP, Head Intellectual Property | Reveal Email/Phone |
8 | Controller | Reveal Email/Phone |
9 | VP Business Development | Reveal Email/Phone |
10 | VP, Clinical Operations | Reveal Email/Phone |
Scholar Rock Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Scholar Rock?
Scholar Rock® is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock's newly elucidated understanding of the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.
keywords:Biotechnology,Healthcare,Healthcare Providers,Pharmaceuticals$358M
Total Funding
190
Number of Employees
$18.2M
Revenue (est)
30%
Employee Growth %
$710.2M
Valuation
N/A
Accelerator
Scholar Rock News
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of...
Two analysts have made estimates for Scholar Rock's earnings. The highest sales estimate is $33.20 million and the lowest is $33.19 million.
Equities analysts forecast that Scholar Rock Holding Co. (NASDAQ:SRRK Get Rating) will announce ($0.68) earnings per share (EPS) for the...
CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,130,803, ...
CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced an oral presentation of TOPAZ Phase 2 trial results by the lead principal investigator, Thom ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $37.6M | 190 | 6% | N/A |
#2 | $42.9M | 190 | 39% | $94.6M |
#3 | $60.9M | 191 | 9% | N/A |
#4 | $51.3M | 192 | 1% | N/A |
#5 | $74.9M | 193 | 8% | N/A |
Scholar Rock Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2014-09-16 | $20.0M | A | ARCH Venture Partners | Article |
2016-01-05 | $36.0M | B | Fidelity Management and Research Company | Article |
2018-01-04 | $47.0M | C | Invus | Article |